TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 452871

Group type: EXPERIMENTAL
Intervention: 1 mg of quinestrol (oral, one tablet once a month)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (oral, one tablet once a month)
Number of subjects: 70
Study: 31028894

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate and salmeterol
Number of subjects: 3416

Group type: COMPARATOR
Intervention: Fluticasone propionate
Number of subjects: 3416
Study: 28088380

Group type: EXPERIMENTAL
Intervention: Aquatic exercise therapy (45min, twice a week for 6 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21
Study: 25832538

Group type: EXPERIMENTAL
Intervention: Multimedia source material plus the Internet platform of Joint Registration System
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 300
Study: 24713186

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Ribavirin (RBV) for 12 weeks
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) + Ribavirin (RBV) for 24 weeks
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Patients achieving SVR-12 (regardless of regimen)
Number of subjects: 334
Study: 22446169

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) - 1 set
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) - 3 sets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercise control
Number of subjects: 0
Study: 19411061

Group type: EXPERIMENTAL
Intervention: Low dose propranolol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 17241875

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 0

Group type: COMPARATOR
Intervention: AT(1) receptor antagonist losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: AT(1) receptor antagonist candesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Candesartan
Number of subjects: 0
Study: 15717509

Group type: EXPERIMENTAL
Intervention: Kinetic therapy (KT) with propofol sedation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Kinetic therapy (KT) without propofol sedation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no KT or propofol sedation)
Number of subjects: 46
Study: 12101331

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 122
Study: 10066989

Group type: EXPERIMENTAL
Intervention: Couples with 1 drug-abusing partner (husband or wife)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Couples with both partners abusing drugs
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Couples with 1 drug-abusing partner during and 1 year after treatment
Number of subjects: 287

Group type: COMPARATOR
Intervention: Non-substance-abusing conflicted couples
Number of subjects: 287
Study: 7644246

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg, 8 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (NaCl solution)
Number of subjects: 10
Study: 2792787

Group type: EXPERIMENTAL
Intervention: Running exercise (REX) group engaged in a 12-week aerobic exercise conditioning program at 70% of their VO2max, 3 times a week for 30 minutes each session.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isometric exercise (IEX) group engaged in a 12-week weight lifting program utilizing large muscle mass at 30% of their maximal voluntary contraction, 3 times a week for 30 minutes each session.
Number of subjects: 40
Study: 973761

Group type: EXPERIMENTAL
Intervention: Interruption of the patent ductus arteriosus (PDA) in 20 patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Medical treatment in 13 patients
Number of subjects: 42
Study: 29600837

Group type: EXPERIMENTAL
Intervention: Functional Training (FT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Traditional Training (TT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 44
Study: 28619659

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 or 300 mg
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666
Study: 26204970

Group type: EXPERIMENTAL
Intervention: Protocolized care in an observation unit
Number of subjects: 0
Study: 23909039

Group type: EXPERIMENTAL
Intervention: Preoperative taxane-based chemotherapy
Number of subjects: 0
Study: 22008302

Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets (Damon 3 MX)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Active self-ligating brackets (In-Ovation R)
Number of subjects: 64
Study: 19593177

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 15
Study: 17000077

Group type: EXPERIMENTAL
Intervention: V.A.C. therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional wound care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 15556824

Group type: EXPERIMENTAL
Intervention: High-dose adenosine infusion (140 microg/kg/min for 22 minutes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beta-endorphin bolus followed by infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone bolus followed by NaCl infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (NaCl bolus for 2 minutes followed by NaCl infusion for 15 minutes)
Number of subjects: 10
Study: 11384898

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 9402541

Group type: EXPERIMENTAL
Intervention: Diagnostic protocol for ocular palsies
Number of subjects: 105
Study: 7667826

Group type: EXPERIMENTAL
Intervention: 1 mg protamine/100 U UFH
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.25 mg protamine/100 U UFH
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.5 mg protamine/100 U UFH
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 mg protamine/100 anti‐Xa U LMWH
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: protamine on LMWH in shed blood
Number of subjects: 15

Group type: COMPARATOR
Intervention: UFH and LMWH
Number of subjects: 15
Study: 2531963

Group type: EXPERIMENTAL
Intervention: Continuous absorbable suture (Dexon)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Continuous nonabsorbable suture (Surgilon)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Interrupted absorbable suture (Dexon)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Overall frequency after 41 months follow-up
Number of subjects: 238
Study: 31041523

Group type: EXPERIMENTAL
Intervention: CXL combined with antifungal medications (CXL‐M)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Antifungal medications alone (M)
Number of subjects: 41
Study: 28495149

Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Sham control (riboflavin alone without removal of the epithelium)
Number of subjects: 205
Study: 25645909

Group type: EXPERIMENTAL
Intervention: Glucose ingestion (75 g)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fructose ingestion (75 g)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Baseline acyl-ghrelin
Number of subjects: 41

Group type: COMPARATOR
Intervention: PYY response after glucose
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: PYY response after fructose
Number of subjects: 41
Study: 22459694

Group type: EXPERIMENTAL
Intervention: ASSIST intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 21747296

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Continuously Moderate-Intensity Exercise (CME)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Aerobic Interval Training (AIT) and Continuously Moderate-Intensity Exercise (CME)
Number of subjects: 28
Study: 19262495

Group type: EXPERIMENTAL
Intervention: Benidipine (4 mg day(-1) increased to 16 mg day(-1))
Number of subjects: 47

Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg day(-1) increased to 10 mg day(-1))
Number of subjects: 47
Study: 18690917

Group type: EXPERIMENTAL
Intervention: 5‐HT and NA reuptake inhibitors (e.g., duloxetine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective 5‐HT reuptake inhibitors and SNRIs
Number of subjects: 0
Study: 12813199

Group type: EXPERIMENTAL
Intervention: Diuretic renogram with furosemide after vigorous intravenous hydration
Number of subjects: 205
Study: 10639612

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham exchange
Number of subjects: 0
Study: 9264050

Group type: EXPERIMENTAL
Intervention: Estazolam drops (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Estazolam tablets (reference formulation, ESILGAN)
Number of subjects: 24
Study: 8319321

Group type: EXPERIMENTAL
Intervention: Nuelin SA (sustained-release theophylline) 250 mg every 12 h plus Nuelin liquid (non-sustained-release theophylline) 100 mg, 200 mg, or 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nuelin SA (sustained-release theophylline) 250 mg every 12 h plus placebo
Number of subjects: 12
Study: 3621870

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg b.w. of TGLVP
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.9% saline i.v.
Number of subjects: 8
Study: 29063598

Group type: EXPERIMENTAL
Intervention: Modified SLIPA with a 120° bend at the bridge point
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional SLIPA insertion method
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study: 28825973

Group type: EXPERIMENTAL
Intervention: High-intensity training (HIT)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 318
Study: 25460263

Group type: EXPERIMENTAL
Intervention: BFNE-R (Brief Fear of Negative Evaluation Scale - Revised)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: FPES (Fear of Positive Evaluation Scale)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Pride responses to positive films
Number of subjects: 98
Study: 23308216

Group type: EXPERIMENTAL
Intervention: Reactive rapid HIV tests
Number of subjects: 62

Group type: COMPARATOR
Intervention: Participants who completed confirmatory testing
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Projected true HIV cases lost at confirmation stage
Number of subjects: 62
Study: 21386766

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 32 mg/day
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 514
Study: 18202320

Group type: EXPERIMENTAL
Intervention: Far infrared (FIR) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilirubin (mimicking FIR therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HO inhibitor (tin protoporphyrin-IX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective knockdown of HO-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FIR therapy in patients undergoing hemodialysis
Number of subjects: 0
Study: 16391189

Group type: EXPERIMENTAL
Intervention: (18)F-FDG SPECT
Number of subjects: 130
Study: 12857503

Group type: COMPARATOR
Intervention: 0.9% saline (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 mg/kg esmolol (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 microg/kg fentanyl (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 mg/kg esmolol combined with 2 microg/kg fentanyl (Group D)
Number of subjects: 60
Study: 11020410

Group type: EXPERIMENTAL
Intervention: Polyacrylic intraocular lens
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Polymethylmethacrylate intraocular lens
Number of subjects: 1202
Study: 8864674

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 61

Group type: COMPARATOR
Intervention: 15 mg prednisolone
Number of subjects: 61
Study: 1624977

Group type: EXPERIMENTAL
Intervention: Counseling/supportive interventions by a community health nurse (CHN)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intervention groups (followed through pregnancy and first 6 months of babies' lives)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (evaluated when infant reached 6 months)
Number of subjects: 30
Study: 6367947

Group type: EXPERIMENTAL
Intervention: S1: CYVADIC (combination chemotherapy with cyclophosphamide, vincristine, Adriamycin, and DTIC administered simultaneously every 4 weeks)
Number of subjects: 246

Group type: COMPARATOR
Intervention: S2: ADIC-CYV (pairs of drugs administered alternating at 4 weekly intervals)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: S1: CYVADIC
Number of subjects: 246

Group type: COMPARATOR
Intervention: S2: ADIC-CYV
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Karnofsky index (KI) 90-100
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Karnofsky index (KI) 50-80
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Karnofsky index (KI) 50
Number of subjects: 246
Study: 31673366

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Early BOS
Number of subjects: 45
Study: 28591082

Group type: EXPERIMENTAL
Intervention: SoluMatrix indomethacin 40 mg 3 times daily
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: SoluMatrix indomethacin 20 mg 3 times daily
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: SoluMatrix indomethacin 40 mg twice daily
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg loading dose followed by 200 mg twice daily
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 25526970

Group type: COMPARATOR
Intervention: Suvorexant 40/30 mg
Number of subjects: 2040

Group type: COMPARATOR
Intervention: Suvorexant 20/15 mg
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 2040
Study: 24965313

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) exercises accompanied by music
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study: 22970149

Group type: EXPERIMENTAL
Intervention: 600 mg/day DHA (from algal oil)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Taste/color matched corn/soybean oil placebo
Number of subjects: 362
Study: 20580201

Group type: EXPERIMENTAL
Intervention: Telecare management
Number of subjects: 405

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 405
Study: 18042824

Group type: EXPERIMENTAL
Intervention: HATS analysis software
Number of subjects: 150

Group type: COMPARATOR
Intervention: Odontorule slide rule (manual measurement)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 150
Study: 15627725

Group type: EXPERIMENTAL
Intervention: Recombinant human leptin (4 microg ml(‐1) kg(‐1) body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study: 11840415

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus carboplatin for four cycles followed by four cycles of paclitaxel plus carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin or carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus topotecan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus liposome‐encapsulated doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus treosulfan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus a platinum compound
Number of subjects: 0
Study: 10544992

Group type: EXPERIMENTAL
Intervention: Client-focused case management
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Client-focused case management plus consumer advocacy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 119
Study: 7560254

Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg every 12 hours (n = 12)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo every 12 hours (n = 6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg every 12 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Warfarin daily for 14 days
Number of subjects: 18
Study: 2182370

Group type: EXPERIMENTAL
Intervention: Nd YAG laser
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Heater probe
Number of subjects: 143

Group type: COMPARATOR
Intervention: No endoscopic therapy (Control)
Number of subjects: 143
Study: 7370482

Group type: EXPERIMENTAL
Intervention: Clomipramine (up to 225 mgs nocte for 8 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (nightly for 8 months)
Number of subjects: 40
Study: 31154289

Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg, s.c., weekly) + Methotrexate (7.5-15 mg, p.o., weekly)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Etanercept (50 mg, s.c., weekly)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination group (Etanercept + Methotrexate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monotherapy group (Etanercept)
Number of subjects: 30
Study: 28060936

Group type: EXPERIMENTAL
Intervention: Royal Jelly (RJ) 1200 mg/tablet, six tablets daily for 8 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 25636315

Group type: EXPERIMENTAL
Intervention: Caribbean Informed Parents and Children Together
Number of subjects: 1833
Study: 23716707

Group type: EXPERIMENTAL
Intervention: Reperfusion
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reperfusion (defined as time to maximum volume of 59% or greater)
Number of subjects: 114
Study: 21122974

Group type: EXPERIMENTAL
Intervention: Automated external defibrillator (AED) presence and instructions visible
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Automated external defibrillator (AED) presence
Number of subjects: 90

Group type: COMPARATOR
Intervention: CPR certificate status
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall performance in simulated cardiac arrest
Number of subjects: 90
Study: 19593546

Group type: EXPERIMENTAL
Intervention: Continuous cardiac output monitoring devices
Number of subjects: 0
Study: 17173898

Group type: EXPERIMENTAL
Intervention: Perfusion mapping with color Doppler ultrasound and laser Doppler flowmeter for TESE biopsies.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Areas with different levels of perfusion marked with needles and biopsies taken for TESE and histology.
Number of subjects: 12
Study: 15510039

Group type: EXPERIMENTAL
Intervention: HSA-coated tympanostomy tubes
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: HSA-coated tympanostomy tubes in patients with perioperative bleeding
Number of subjects: 179

Group type: COMPARATOR
Intervention: Uncoated tympanostomy tubes (control)
Number of subjects: 179
Study: 11466802

Group type: EXPERIMENTAL
Intervention: Encouragement not to smoke
Number of subjects: 0
Study: 9631964

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty followed electively with Gianturco Roubin II stents (group I)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty alone (group II)
Number of subjects: 104
Study: 7948056

Group type: EXPERIMENTAL
Intervention: Trimipramine at a mean dose of 166 +/- 48 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Discontinuation of trimipramine
Number of subjects: 19
Study: 3282026

Group type: EXPERIMENTAL
Intervention: Telephone reminder
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Mailed reminder
Number of subjects: 787

Group type: COMPARATOR
Intervention: Control group (no reminder)
Number of subjects: 787
Study: 31964674

Group type: EXPERIMENTAL
Intervention: Working over 55 hours per week
Number of subjects: 2706

Group type: COMPARATOR
Intervention: Working 40-44 hours per week
Number of subjects: 2706
Study: 30501611

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with 0.1 mg/kg dexamethasone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (control)
Number of subjects: 50
Study: 27581475

Group type: EXPERIMENTAL
Intervention: High-potassium diet (HKD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 20
Study: 24127818

Group type: EXPERIMENTAL
Intervention: Combination therapy (dutasteride 0.5 mg + tamsulosin 0.4 mg)
Number of subjects: 4844

Group type: COMPARATOR
Intervention: Tamsulosin monotherapy
Number of subjects: 4844

Group type: COMPARATOR
Intervention: Dutasteride monotherapy
Number of subjects: 4844
Study: 23234237

Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention for GPs on performing a narrative doctor-patient dialogue and medication review.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control group).
Number of subjects: 0
Study: 20522354

Group type: EXPERIMENTAL
Intervention: TIVA with propofol and remifentanil
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 18931605

Group type: EXPERIMENTAL
Intervention: Nutramigen AA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Neocate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutramigen LIPIL
Number of subjects: 0
Study: 16705491

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for 4 hours/week for two weeks after standard job search assistance for two weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard job search assistance for 4 hours/week for four weeks
Number of subjects: 0
Study: 14617595

Group type: EXPERIMENTAL
Intervention: Remifentanil with morphine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 91
Study: 10719942

Group type: EXPERIMENTAL
Intervention: Diaspirin cross-linked hemoglobin (DCLHb), 250-ml infusions, up to three infusions
Number of subjects: 209

Group type: COMPARATOR
Intervention: Packed erythrocytes (pRBCs), three units
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: DCLHb
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control (pRBCs)
Number of subjects: 209